PATH | VRL
Menu

An N-terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate

This article, published in Clinical and Vaccine Immunology, reports on the immunogenic potential of the N-terminal Plasmodium falciparum sexual-stage antigen (Pfs230C1) as a component of an effective transmission-blocking vaccine. According to the authors' findings, this antigen was shown to induce antibodies in mice that exhibited functional activity as determined by two assays, supporting the continued advancement of the Pfs230C1 antigen as a component of a transmission-blocking vaccine and the continued use of the scalable baculovirus expression system for generation of complex malaria proteins. 

Author: Lee SM, Wu CK, Plieskatt JL, Miura K, Hickey JM, King CR

Published: 2017

» Visit web page (English)

(Located at cvi.asm.org)

Citation: Lee SM, Wu CK, Plieskatt JL, Miura K, Hickey JM, King CR. An N-terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate. Clinical and Vaccine Immunology. 2017;24(10):e00140-17.

Resource types: Peer-reviewed journal

Diseases/vaccines: Malaria

Topics: Disease/vaccine specific information

Regions: Global